AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00112736 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temsirolimus
Description: Given IV
Study NCT00112736 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Description: Undergo surgical resection
Study NCT00112736 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT00112736 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT02656277 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Decision Tool
Study NCT02656277 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Information on Shoulder Dislocation
Study NCT00973752 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Orally during Induction, Consolidation 1, CNS, Consolidation 2, and Continuation therapy.
Study NCT00973752 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Intravenously during Induction, CNS, Consolidation 2 and Continuation Therapy
Study NCT00973752 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Intravenously during Induction, CNS, and Consolidation 2 therapy
Study NCT00973752 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG-asparaginase
Description: Intravenously during Induction, Consolidation 1, CNS, and Consolidation 2 therapy
Study NCT00973752 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Intrathecally during Induction and CNS therapy
Study NCT00973752 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Intrathecally during Induction, CNS, and Continuation Therapy
Study NCT00973752 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib
Description: Orally during Induction, Consolidation 1, CNS, Consolidation 2 and Continuation Therapy
Study NCT00973752 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clofarabine
Description: Intravenously during Consolidation 1 Therapy
Study NCT00973752 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 6 Mercaptopurine
Description: Orally during CNS, Consolidation 2 and Continuation Therapy
Study NCT02570503 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: Ropivacaine (5mg/ml)-50ml
Study NCT02570503 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac
Description: ketorolac (30mg/ml)- 1 ml
Study NCT02570503 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clonidine
Description: clonidine (0.1mg/ml)- 0.8ml
Study NCT02570503 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epinephrine
Description: epinephrine (1mg/ml)-1ml
Study NCT02570503 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% sodium chloride
Description: Sodium chloride 0.9%- 47.7 ml
Study NCT02570503 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.9% sodium chloride
Description: Sodium chloride 0.9%- 47.7 ml
Study NCT01476423 — intervention group
Intervention type: DRUG
Intervention: activated recombinant human factor VII
Description: A prospective, observational multi-national registry collecting data and evaluating the efficacy and safety of rFVIIa in patients with GT with past or present refractoriness to platelet transfusions. The registry will also collect data from a broader range of GT patients treated with systemic haemostatic treatment (with or without antifibrinolytic drugs or other agents) used in the clinics. Data collection will continue for a maximum of six years. Baseline data as well as data obtained during either bleeding episodes or invasive procedures/surgeries will be recorded in the registry.
Study NCT02475538 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electroacupuncture
Description: Gradual Tapering Benzodiazepines will be tapered off over four weeks. The subjects will be told by a blinded researcher to reduce their daily dose by 25% in the 1st and 2nd week. For the remaining 50%, subjects will be asked to reduce the dose by 12.5% each time for 3-4 days in the 3rd and 4th week. Subjects who are unable to taper according to the suggested plan can reduce dose at a slower pace.~Electroacupuncture The subjects will be treated with electroacupuncture at bilateral Sishencong (EX-HN1), Anmian, Shuaigu (GB8), Touwei (ST8), Taiyang (EX-HN5), Toulinqi (GB15), Neiguan (PC6), Shenmen (HT7), Sanyinjiao (SP6), Taichong (LV3), and unilateral Yintang (EX-HN3), Shenting (GV24), and Baihui (GV20). De qi is achieved if possible. The intensity of electric-stimulation will be adjusted up to a level the subject can tolerate without undue discomfort. The needles will be left for 30 min.
Study NCT02475538 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo acupuncture
Description: Gradual Tapering The gradual tapering procedure will be the same as in the Electroacupuncture combined with gradual tapering group.~Placebo acupuncture Placebo needles designed by Streitberger will be used. The placebo needles are inserted to the site 1 inch beside the acupoints of the electroacupuncture group in order to avoid acupressure effect. The needles are held by surgical tape or hair pin to imitate the procedure of acupuncture. The needles are connected to an electric-stimulator with zero frequency and amplitude. The number, duration and frequency of treatment session will be the same as in the Electroacupuncture combined with gradual tapering group.
Study NCT03446625 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Resveratrol
Description: Resveratrol treatment (2 g/day) will be administered for 9 days, starting from oocyte maturation day.
Study NCT03446625 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Resveratrol
Description: Resveratrol treatment (2 g/day) will be administered for 9 days, starting from oocyte maturation day.
Study NCT03446625 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo treatment (2 g/day) will be administered for 9 days, starting from oocyte maturation day.
Study NCT03446625 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo treatment (2 g/day) will be administered for 9 days, starting from oocyte maturation day.
Study NCT04345341 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TAP block with liposomal bupivacaine and bupivacaine
Description: injecting the mixture of bupivacaine with liposomal bupivacaine in transversus abdominis plane to block the somatic nerves
Study NCT01723735 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alirocumab
Description: Pharmaceutical form: solution for injection~Route of administration: subcutaneous
Study NCT01723735 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezetimibe
Description: Pharmaceutical form: overencapsulated tablet~Route of administration: oral
Study NCT01723735 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezetimibe Placebo
Description: Pharmaceutical form: capsule~Route of administration: oral
Study NCT01723735 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fenofibrate
Description: Pharmaceutical form: tablet~Route of administration: oral
Study NCT01464086 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: whole body MRI
Description: whole body MRI at inclusion, one and two years
Study NCT03473236 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GB002
Description: Inhaled GB002
Study NCT03473236 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Generic Dry Powder Inhaler
Description: dry powder inhaler used for inhalation of active drug or placebo
Study NCT03473236 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Inhaled placebo
Study NCT02692937 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Neurolysis
Study NCT02692937 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional neck-specific exercise program
Study NCT02692937 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Traditional neck-specific exercise program
Study NCT01112137 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Study NCT01112137 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Study NCT04643275 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BTL-899
Description: Treatment with study device.
Study NCT01863459 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine Dimesylate
Study NCT01863459 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT01383603 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cat-PAD
Description: Intradermal injection 1 x 4 administrations 4 weeks apart
Study NCT02752594 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: probiotic
Description: Probiotic was administered for a period of 14 consecutive days. Saliva was collected on Day 1, before intervention and on Day 15, after intervention
Study NCT02752594 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: probiotic
Description: Probiotic was administered for a period of 14 consecutive days. Saliva was collected on Day 1, before intervention and on Day 15, after intervention
Study NCT02752594 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo was administered for a period of 14 consecutive days. Saliva was collected on Day 1, before intervention and on Day 15, after intervention
Study NCT02752594 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: placebo
Description: placebo was administered for a period of 14 consecutive days. Saliva was collected on Day 1, before intervention and on Day 15, after intervention
Study NCT00534365 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: tension-free vaginal tape
Description: Retropubic mid-urethral sling
Study NCT00534365 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TVT-SECUR device
Description: Mid-urethral mini-sling
Study NCT02372643 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: clitoral, transvaginal and transrectal ultrasound
Description: Doppler Ultrasound assessment of clitoral hemodynamics will be performed in all subjects. Transvaginal and transrectal ultrasound will be performed in subjects giving their consent to these procedures.
Study NCT02588599 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Erchonia LUNULA
Description: Active low level laser light therapy
Study NCT04783350 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial alternating current stimulation (tACS)
Description: tACS will be administered to the left angular gyrus at gamma frequency to improve cognitive functioning (MoCA score) and resting-state EEG signatures.
Study NCT02585401 — intervention group
Intervention type: DRUG
Intervention: Eylea (Aflibercept, VEGF Trap-Eye, BAY86-5321)
Description: The physician questionnaire will contain primarily closed-ended questions (e.g., multiple choice, true/false), with few free-text response fields, eliciting responses measuring physician knowledge and understanding of the key information in the Eylea vial preparation instruction card, the intravitreal injection procedure video, and the product monograph.
Study NCT03426670 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: OraQuick HIV Self-Test
Description: OraQuick® HIV Self-Test is an in-vitro diagnostic medical device that is used for self-testing of antibodies for HIV-1 and HIV-2 in oral fluid. This test is intended as an aid to detect antibodies to HIV-1 and HIV-2 from infected individuals.
Study NCT03053375 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MDCure
Description: Battery powered portable pulsed electromagnetic therapy device
Study NCT03053375 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: MDCure
Description: Battery powered portable pulsed electromagnetic therapy device
Study NCT00656929 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3
Description: Vitamin D3 (cholecalciferol) 50 mcg (2000 IU) daily x 3 months
Study NCT00656929 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets
Study NCT03315741 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pirfenidone 267 MG [Esbriet]
Description: Tolerability of drug
Study NCT01927497 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biological mesh assisted perineal closure
Description: The eAPR procedure will be performed in an identical way as described for the control arm of the study, and this is preferably followed by an omental plasty. The intervention in the experimental arm consists of suturing an acellular biological mesh derived from porcine dermis in the pelvic floor defect (Strattice™, 6x10 cm). The mesh will be sutured at each side of the coccyx or distal sacrum with Prolene or PDS to the discretion of the surgeon. Laterally, the mesh is attached to the remainings of the levator complex and, anteriorly, to the transverse perineal muscle or posterior vaginal wall. A suction drain will be inserted and positioned on top of the mesh. The perineal subcutaneous fat and skin will be subsequently closed in layers similar to primary simple closure as performed in the standard arm.
Study NCT01927497 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Primary perineal closure
Description: The perineal phase of the APR will be performed according to the principles of an extralevator APR, which means that the levator muscles will be laterally transected in order to leave a muscular cuff around the tumour. The coccyx will not be routinely resected, but only if indicated based on surgical exposure or oncological principles. The extent of excision of perineal skin and ischioanal fat will be as limited as oncologically justified. Preferably, an omental plasty is positioned in the pelvic cavity following resection. Closure of the perineum in the control arm consists of stitching the perineal subcutaneous fat together using interrupted Vicryl sutures in one or two layers. Subsequently, the skin will be closed using interrupted sutures according to the preference of the surgeon. Placement of a transabdominal or transperineal drain will be at the discretion of the surgeon.
Study NCT04614896 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Transoral ultrasound of tongue tumors
Description: A transoral ultrasound scan of tongue tumors will be performed to assess the depth of invasion of the tumor
Study NCT02804334 — intervention group
Intervention type: PROCEDURE
Intervention: Psychiatric Questionnaires
Study NCT02804334 — intervention group
Intervention type: PROCEDURE
Intervention: Blood draw
Study NCT04854343 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Secretory leukocyte protease inhibitor (SLPI) in prostate cancer
Description: 7 ml of peripheral blood and a urine sample for the determination of SLPI concentration. Blood samples will be promptly processed to obtain sera; both sera and urine will be stored at -80°C in the laboratory. The levels of SLPI in the serum and in the urine will be quantitated by an ELISA assay by using the Human SLPI Quantikine ELISA Kit. SLPI level will be measured at diagnosis and during the follow-up (3, 9, 15 months and in case of progression).~Immunohistochemistry protocol for SLPI immunostaining to investigate SLPI levels prostate tissue
Study NCT04854343 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Determination of molecular alterations
Description: The presence of ETS translocation (or of ETS overexpression) will be tested on bioptic samples in each patient as for routine diagnostic procedures. First, ERG overexpression will be investigated by ERG immunostaining. The samples negative for ERG immunostaining will be studied for TMPRSS2-ERG translocation either by in situ FISH or by a translocation-specific RT-PCR. Next, the biopsies negative for TMPRSS2-ERG will be tested for the overexpression of other ETS proteins (ETV1, ETV4, ETV5 and for others rarely occurring ETS). When possible, it will be determined the status of pTEN gene, the tumor suppressor most frequently lost in prostate patients. The patients negative for the overexpression of the ETS proteins will be tested for SPINK1.
Study NCT04854343 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Secretory leukocyte protease inhibitor (SLPI) Healthy
Description: SLPI level will be measured also in the serum and in the urine from controls (patients with BPH and healthy subjects).~7 ml of peripheral blood and a urine sample for the determination of SLPI concentration. Blood samples will be promptly processed to obtain sera; both sera and urine will be stored at -80°C in the laboratory. The levels of SLPI in the serum and in the urine will be quantitated by an ELISA assay by using the Human SLPI Quantikine ELISA Kit.
Study NCT03515577 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo PET/CT
Study NCT03515577 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluciclovine F18
Description: Given fluciclovine F18
Study NCT03515577 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gallium Ga 68-labeled PSMA-11
Description: Given IV
Study NCT03515577 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03515577 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT
Study NCT04140968 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Utrogestan
Description: 300mg Utrogestan (1 tablet 100mg + 1 tablet 200mg) in the second and third menstrual cycle daily from cycle day 15 to 26.
Study NCT00359255 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education manual
Description: The control arm was given education on stroke, the affected arm post strooke, bone health, and healthy living. This information was given in a booklet format and administered once weekly by the site coordinator.
Study NCT00359255 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: An inpatient homework based exercise program for the upper limb post stroke
Description: The experimental arm was given arm exercises graded based on motor impairment and administered by the site coordinator. The exercises were given in a booklet with written and photographic instructions. These exercises were monitored on a twice-weekly basis.~The intervention was to be completed once daily for 45 minutes, 5 days per week, and supervised by the site coordinator. Exercises consisted of range of motion, strengthening, and use of the arm in daily activites such as buttoning, pouring and throwing.
Study NCT00310765 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pregabalin 75 or 150 mg BID for 7 weeks followed by open label pregabalin 150 mg BID for 4 weeks
Description: First 7 weeks 75 or 150 mg of pregabalin po BID. Start at 75 mg and increase to 150 mg po BID if no improvement after 3 days and treat for 7 weeks. Followed by open label pregabalin for 4 weeks at 150 mg BID
Study NCT00310765 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin 75 or 150 mg BID for 7 weeks followed by open label pregabalin 150 mg BID for 4 weeks
Description: First 7 weeks 75 or 150 mg of pregabalin po BID. Start at 75 mg and increase to 150 mg po BID if no improvement after 3 days and treat for 7 weeks. Followed by open label pregabalin for 4 weeks at 150 mg BID
Study NCT00310765 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo first followed by open label pregabalin
Description: Look alike placebo 75 mg po BID and increase to 150 mg BID after 3 days if no improvement for 7 weeks. Open label pregabalin 150 mg BID for last 4 weeks of study.
Study NCT00895635 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treadmill Exercise Training
Description: 60-minute sessions of supervised treadmill exercise training three times a week for 12 weeks
Study NCT00895635 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Arm Ergometry Exercise Training
Description: 60-minute sessions of supervised aerobic arm exercise training using an arm ergometer three times a week for 12 weeks
Study NCT00895635 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Usual care for PAD
Study NCT03137992 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single dose of placebo inhalation powder administered by test and reference dry powder inhalers.
Study NCT03137992 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test Product (tiotropium bromide inhalation powder)
Description: Double-Blind: Single dose of test product 18 mcg of test product Open-Label: once daily administration of test product (tiotropium bromide inhalation powder) 18 mcg administered by test dry powder inhaler.
Study NCT03137992 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Reference Product (Spiriva®)
Description: Reference product (Spiriva®) 18 mcg.
Study NCT03741686 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: konjac glucomannan
Description: Konjac-mannan fiber-enriched biscuits (0.5 g/412KJ \[100kcal\] of glucommanan)
Study NCT03741686 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: wheat bran
Description: Wheat bran (hard red wheat bran) fiber enriched biscuits
Study NCT02798393 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Infrared Phototherapy
Description: Subjects will wear a cuff on their extremities for a set period of time at set intervals over a period of several weeks. The cuff will emit the Infrared Phototherapy treatment (or sham if randomized to the non-treat group).